General Partner & Global Head of Healthcare
B Capital — $6B+ AUM Multi-Stage Global VC
"Technological advancements in biology, AI and automation are transforming the industry, with business models seeing the convergence of traditional players in novel ways."Robert Mittendorff, MD — B Capital Healthcare Fund I Launch, 2023
Robert Mittendorff does not fit neatly into a single category. He is a board-certified emergency physician, a biomedical engineer, an MBA-holding management consultant, a surgical robotics executive, and now one of the most influential healthcare venture capitalists in the United States - currently writing checks of $15 million to $60 million at B Capital, a global multi-stage firm with over $6 billion in assets under management.
The career arc that brought him here is not so much a pivot as a deliberate layering. Johns Hopkins undergraduate in biomedical engineering. Fellowship at MIT. MD from Harvard Medical School. Emergency medicine residency at Stanford. MBA from Harvard Business School. A stint as a management consultant at BCG. Portfolio strategy at Merck. Emergency physician shifts at Kaiser Permanente - which he kept doing, in parallel, for years. An executive role at Hansen Medical launching surgical robots. And then, nearly a decade building out healthcare investing at Norwest Venture Partners before B Capital came calling in April 2021.
"B Capital has decades of collective operating experience in the healthcare industry and a deep technical focus that allows us to identify and support the best companies in the space."
Robert Mittendorff, MD — B CapitalWhat makes Mittendorff unusual is not the credential collection - plenty of people in venture capital have impressive CVs. It is the way he has built cross-domain fluency that genuinely informs his investment work. When he sat across the table from founders building AI-driven spinal implants at Carlsmed, or cell therapy companies like Triumvira, or pharmacy benefit manager disruptors like CapitalRx, he was not relying on pattern-matching from the outside. He understood the biology, the clinical workflow, the regulatory pathway, and the market structure, all at once.
That operational credibility is rare. It shapes both who returns his calls and which companies survive the B Capital diligence process.
BCG management consultant - learned to think in frameworks, not just biology. Also works in portfolio strategy at Merck, gaining a pharma insider view. Practices emergency medicine at Kaiser Permanente.
VP of Marketing and Business Development at Hansen Medical (Nasdaq: HNSN). Launches the Magellan and Sensei X surgical robots. Leads commercial partnerships with GE, Siemens, Philips, and St. Jude Medical. The company is later acquired by Auris Health, which Johnson & Johnson buys for $3.4 billion.
Joins Norwest Venture Partners as Partner and Co-Head of Healthcare. Begins building a track record that will eventually exceed $10 billion in exit value. Backs early-stage bets including Misfit Wearables (acquired by Fossil), Health Catalyst (HCAT IPO), and iRhythm Technologies.
Joins B Capital in April as General Partner and Global Head of Healthcare. Begins building what will become B Capital's inaugural $500M+ dedicated healthcare fund.
B Capital Healthcare Fund I closes in March 2023, with over $500 million committed across Healthcare Fund I and Growth Fund III. Invests in companies spanning CapitalRx, Carlsmed, Nalu Medical, Triumvira, Atomwise, and Carrick, among others.
Active board member at ARTBIO (Series B, $130M) and Judi Health (Series F, $250M), among others. Continues to expand B Capital's global healthcare franchise across US, Asia, and Europe.
Disrupting pharmacy benefit management with a unified dispensing platform. Board member.
AI-enabled, patient-specific spinal implant solutions. Series C, $64M round. Board member.
Next-generation micro-implantable neurostimulation devices. Series E, $85M round. Board member.
Engineered T cell therapies targeting hematologic malignancies. Board member.
AI-driven small molecule drug discovery platform. Board member.
Targeted alpha radiotherapy developer. Series B, $130M round (July 2025). Board member.
Whole-person care platform. Series F, $250M round (September 2025). Board member.
Brain-computer interface technology for neural disorders. Series C, $100M round.
Inhaled therapies for pulmonary fibrosis. Series C, $180M round. Observer.
Earlier investments at Norwest Venture Partners include Misfit Wearables (acquired by Fossil Group), Health Catalyst (Nasdaq: HCAT), iRhythm Technologies, Silk Road Medical, Neocis, TigerConnect, Talkspace, Omada Health, and others. Combined exit value exceeds $10 billion.
"We are witnessing unprecedented innovation across the healthcare landscape."Robert Mittendorff, MD — On closing B Capital Healthcare Fund I
Venture capital tends to reward specialization. The best healthcare investors are usually either clinicians who learned finance, or finance people who learned healthcare. Mittendorff did both, serially, with enough operational stops in between to understand how products actually get built and sold.
At Hansen Medical, before "surgical robotics" was a mainstream category, he was out in hospitals trying to convince cardiac interventionalists to adopt a catheter navigation robot. The Sensei X and Magellan systems were genuinely novel - electrophysiology labs had never seen anything like them. Selling that required understanding hospital procurement, clinical protocols, reimbursement codes, and competitive medical device sales all at once. The company was eventually acquired by Auris Health, which J&J acquired for $3.4 billion. Mittendorff had already moved on to venture.
"He has been involved in investments and associated exits with public equity value or acquisition value exceeding $10 billion."
B Capital Group profile of Robert MittendorffThe nearly ten years at Norwest Venture Partners gave him time to develop a real track record. The exits speak directly: iRhythm Technologies, now a publicly traded cardiac monitoring company; Health Catalyst, a healthcare data analytics platform that went public on Nasdaq; Misfit Wearables, the consumer health tracker acquired by Fossil Group. These were not lucky bets. They were companies where he sat on boards, worked with leadership teams, and drove value over years.
B Capital is a different vehicle. Co-founded with Boston Consulting Group, it operates with a distinctive mix of financial capital and operational consulting firepower - a model designed to help portfolio companies not just with check-writing but with strategy, market access, and talent. For Mittendorff, who had previously worked at BCG himself, this was familiar territory. He joined in April 2021 as the firm built out its dedicated healthcare investing practice from scratch.
The Healthcare Fund I close in March 2023 - over $500 million committed, 20+ portfolio companies across three continents, spanning digital health to biotech to medtech - was the visible result. Behind it was the conviction that AI, biology, and automation were converging to create a once-in-a-generation window for healthcare investment. The fund's investment range, $15 million to $60 million on first check, reflects a sweet spot for companies that have demonstrated product-market fit and are ready to scale.
The portfolio that has emerged reflects an investor who trusts clinical intuition. Carlsmed uses AI to design patient-specific spinal implants. Nalu Medical makes micro-implantable neurostimulators small enough to implant through a needle. Triumvira is engineering T cell therapies. ARTBIO is pursuing targeted alpha radiotherapy. These are not safe bets on digitizing existing workflows. They are bets on genuinely new biology and genuinely new devices.
Through all of it, Mittendorff has maintained his medical license and continued seeing patients as an emergency physician at Kaiser Permanente. That detail matters more than it sounds. Emergency medicine is the discipline that forces you to make consequential decisions with incomplete information, under time pressure, without the luxury of waiting for the perfect data set. It is, in many ways, excellent training for venture capital.
He also happens to support Manchester United and was a varsity athlete at Johns Hopkins. The full picture is of someone who genuinely likes competing - at the bedside, on the field, and in the deal room.